We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Emergent Biosolutions (EBS - Free Report) shares ended the last trading session 14.4% higher at $7.24. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.9% gain over the past four weeks.
Emergent BioSolutions’ stock rose as investors reacted positively to new government contracts and financial moves. The company secured a $24 million BARDA contract modification to supply Cyfendus, supporting its anthrax preparedness business. The company also won a three-year Canadian government standing offer to supply Narcan nasal spray, expanding its government business. In addition, the company repurchased $75 million of debt at a discount, strengthening its balance sheet and reducing outstanding debt.
This biopharmaceutical company is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of -134.9%. Revenues are expected to be $123.33 million, down 46.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Emergent Biosolutions, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on EBS going forward to see if this recent jump can turn into more strength down the road.
Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, MaxCyte, Inc. (MXCT - Free Report) , closed the last trading session 0.9% higher at $1.08. Over the past month, MXCT has returned -16.4%.
For MaxCyte, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.08. This represents a change of +33.3% from what the company reported a year ago. MaxCyte currently has a Zacks Rank of #2 (Buy).
View the Zacks #1 Rank List
Image: Bigstock
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Emergent Biosolutions (EBS - Free Report) shares ended the last trading session 14.4% higher at $7.24. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.9% gain over the past four weeks.
Emergent BioSolutions’ stock rose as investors reacted positively to new government contracts and financial moves. The company secured a $24 million BARDA contract modification to supply Cyfendus, supporting its anthrax preparedness business. The company also won a three-year Canadian government standing offer to supply Narcan nasal spray, expanding its government business. In addition, the company repurchased $75 million of debt at a discount, strengthening its balance sheet and reducing outstanding debt.
This biopharmaceutical company is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of -134.9%. Revenues are expected to be $123.33 million, down 46.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Emergent Biosolutions, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on EBS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, MaxCyte, Inc. (MXCT - Free Report) , closed the last trading session 0.9% higher at $1.08. Over the past month, MXCT has returned -16.4%.
For MaxCyte, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.08. This represents a change of +33.3% from what the company reported a year ago. MaxCyte currently has a Zacks Rank of #2 (Buy).